Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Chella

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Translational Oncology|December 22, 2024
Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patientsMartina Ruglioni, Iacopo Petrini, Stefania Crucitta, et al.
The International Journal of Biological Markers|September 30, 2010
Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesotheliomaAlfonso Cristaudo, Rudy Foddis, Alessandra Bonotti, et al.
Scientific Reports|March 7, 2019
Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomasGreta Alì, Rossella Bruno, Anello Marcello Poma, et al.
Frontiers in Oncology|February 27, 2023
Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancerGreta Alì, Anello Marcello Poma, Iosè Di Stefano, et al.
Pharmacological Research|May 3, 2021
Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectivesFederico Cucchiara, Iacopo Petrini, Chiara Romei, et al.
Frontiers in Oncology|January 25, 2021
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung CancerFederico Cucchiara, Marzia Del Re, Simona Valleggi, et al.
International Journal of Molecular Sciences|August 17, 2019
Understanding the Mechanisms of Resistance in <i>EGFR</i>-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment StrategyMarzia Del Re, Stefania Crucitta, Giulia Gianfilippo, et al.
The International Journal of Biological Markers|September 21, 2016
Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesotheliomaAlessandra Bonotti, Silvia Simonini, Elena Pantani, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 18, 2002
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluationAntonio Marchetti, Caterina Pellegrini, Fiamma Buttitta, et al.
British Journal of Cancer|November 7, 2018
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib responseMarzia Del Re, Paola Bordi, Eleonora Rofi, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Translational Oncology|December 22, 2024
Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patientsMartina Ruglioni, Iacopo Petrini, Stefania Crucitta, et al.
The International Journal of Biological Markers|September 30, 2010
Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesotheliomaAlfonso Cristaudo, Rudy Foddis, Alessandra Bonotti, et al.
Scientific Reports|March 7, 2019
Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomasGreta Alì, Rossella Bruno, Anello Marcello Poma, et al.
Frontiers in Oncology|February 27, 2023
Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancerGreta Alì, Anello Marcello Poma, Iosè Di Stefano, et al.
Pharmacological Research|May 3, 2021
Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectivesFederico Cucchiara, Iacopo Petrini, Chiara Romei, et al.
Frontiers in Oncology|January 25, 2021
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung CancerFederico Cucchiara, Marzia Del Re, Simona Valleggi, et al.
International Journal of Molecular Sciences|August 17, 2019
Understanding the Mechanisms of Resistance in <i>EGFR</i>-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment StrategyMarzia Del Re, Stefania Crucitta, Giulia Gianfilippo, et al.
The International Journal of Biological Markers|September 21, 2016
Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesotheliomaAlessandra Bonotti, Silvia Simonini, Elena Pantani, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 18, 2002
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluationAntonio Marchetti, Caterina Pellegrini, Fiamma Buttitta, et al.
British Journal of Cancer|November 7, 2018
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib responseMarzia Del Re, Paola Bordi, Eleonora Rofi, et al.
Pageof 12